Alkyl Amines Chemicals sees pharma demand and margin expansion lift earnings

Investment View and Quarterly Performance

Motilal Oswal Financial Services Limited retained its Neutral rating on Alkyl Amines Chemicals in its August 4, 2026 result update, with a target price of Rs 1,950. The target implied only 1 per cent upside from the report's CMP of Rs 1,921.

The company delivered a strong 1QFY27 operating performance, supported by effective raw-material cost pass-through and higher operating leverage. Gross sales increased 30.2 per cent year on year to Rs 5.28 billion, substantially ahead of Motilal Oswal's Rs 4.26 billion estimate.

Gross margin improved to about 49 per cent, expanding by roughly 340 basis points both year on year and sequentially. EBITDA rose 74 per cent year on year to Rs 1.34 billion, while EBITDA margin expanded 640 basis points year on year and 700 basis points quarter on quarter to 25.3 per cent. Employee costs were 6.9 per cent of sales, compared with 6.7 per cent in 1QFY26, while other expenses declined to 17.1 per cent of sales from 20.2 per cent.

Adjusted PAT increased 91 per cent year on year and 2.1 times quarter on quarter to Rs 946 million, versus the broker's estimate of Rs 473 million. The quarter therefore outperformed Motilal Oswal's expectations across revenue, profitability and earnings.

Growth Outlook and Business Drivers

Motilal Oswal expects growth momentum to improve steadily on rising pharmaceutical demand, particularly for peptides, together with healthy demand from agrochemicals and rubber chemicals. The broker has identified the following additional growth drivers:

• Market-share expansion in existing products and entry into new product categories.
• Planned commercialisation of a new product at the Kurkumbh facility in 2QFY27.
• Additional products in the research and development pipeline.
• Continued development of high-quality products through the in-house R&D facility.
• Anti-dumping duty on acetonitrile and scope for higher capacity utilisation, which could increase operating leverage.

Earnings Estimates and Revisions

Following the quarterly outperformance, Motilal Oswal increased its FY27E and FY28E revenue estimates by 8 per cent and 5 per cent, respectively. EBITDA estimates were raised by 23 per cent and 14 per cent, while PAT and EPS estimates were increased by 28 per cent and 17 per cent for FY27E and FY28E, respectively.

The broker estimates FY26 to FY28 revenue, EBITDA and PAT CAGRs of 11 per cent, 16 per cent and 19 per cent, respectively, compared with an FY26 EBITDA margin of 18.5 per cent. Export revenue is expected to account for 25 per cent of total revenue in both FY27E and FY28E. Motilal Oswal also expects Alkyl Amines Chemicals to remain a net-cash company.

Valuation and Key Considerations

Motilal Oswal values Alkyl Amines Chemicals at 40 times FY28E EPS to derive its target price of Rs 1,950. The Neutral recommendation reflects the limited implied upside from the report's CMP of Rs 1,921 despite the strong quarterly performance and upward earnings estimate revisions.

The report does not specify separate downside risks. However, the investment case depends on sustained demand from the pharmaceutical, agrochemical and rubber chemical sectors; successful commercialisation of new products; capacity utilisation gains; continued raw-material cost pass-through; and delivery of the expected margin performance.